Kingsley L. Taft

Kingsley L. Taft

Partner Co-Chair, Life Sciences Practice
Kingsley L. Taft

Kingsley Taft is a senior partner and national co-chair of Goodwin's Life Sciences Practice and member of the Allocations Committee. He represents emerging to mature life sciences companies in all aspects of their business and legal affairs, including company formation, venture financings, strategic alliances, M&A, IPOs and other financing and commercial transactions. Mr. Taft has extensive experience in assisting clients with JVs, strategic alliances, licenses and collaborations.

Mr. Taft has been recognized as a leading life sciences attorney by numerous legal guides. He has been annually ranked for more than a decade in Chambers USA: America’s Leading Lawyers for Business (Nationwide, Life Sciences: Corporate/Commercial – Band 1). Mr. Taft was inducted into the LMG Life Sciences Hall of Fame, an honor recognizing only a handful of attorneys for their industry contributions.

Before attending Harvard Law School, Mr. Taft earned a B.S in Chemistry from Yale University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Mr. Taft regularly serves as outside general counsel to biotechnology, pharmaceutical, medical device and medtech companies, closely advising management and directors as these companies raise capital, in-license and acquire IP and other assets, and then partner their technology, all with a view towards growth and liquidity.

Experience

ERFAHRUNG

工作经历

Representative Matters

REFERENZMANDATE

代表事项

Strategic Alliances and M&A
  • Warp Drive Bio in its strategic collaboration with Roche on novel classes of antibiotics, valued up to $387 million
  • Dimension Therapeutics in its $151 tender offer and contested sale to Ultragenyx
  • Teva Pharmaceuticals in the sale of its specialty global women’s health business for a combined value of $2.5 billion, including sale of Paragard® business to CooperSurgical for $1.1 billion, ex-U.S. women’s health business to CVC Capital Partners for $703 million, and Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
  • Delinia Therapeutics in its sale to Celgene, valued up to $775 million with up-front payment of $300 million
  • Pieris Pharmaceuticals in its strategic collaboration with AstraZeneca to develop novel inhaled drugs that leverage Pieris’ Anticalin platform, for deal value of up to $2.1 billion
  • Royalty Pharma in its acquisition from Perrigo Company of royalty rights to Tysabri, for up to $2.8 billion
  • Pieris Pharmaceuticals in its collaboration with Servier for a dual-checkpoint inhibitor and up to seven other immuno-oncology bispecific drug candidates, for a deal value of up to €1.7 billion
  • Teva Pharmaceuticals in its global agreement with Regeneron for the phase 3 novel nerve growth factor antibody fasinumab, for $250 million upfront and a share in its global commercial value
  • Moderna Therapeutics in numerous strategic transactions with AstraZeneca, Alexion and Merck with aggregate upfront deal value of more than $650 million; most recently, in its strategic collaboration with Merck for mRNA-based personalized cancer vaccines, with an upfront payment of $200 million
  • Morgan Stanley as financial advisor to Stemcentrx in its sale to AbbVie for $5.8 billion in cash and stock, and up to an additional $4 billion in cash in success-based milestone payments
  • Intellia Therapeutics in its multi-year collaboration with Regeneron on CRISPR/Cas gene-editing technology for in vivo therapeutic development, with $75 million upfront and potential milestone and royalty payments
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, valued up to $600 million with up-front and near-term payments of $225 million
  • Blueprint Medicines in its collaboration with Roche, up to $1 billion in value with $45 million upfront
  • Surface Oncology in its collaboration with Novartis to develop next generation immunotherapeutics, with Surface to receive up to $170 million in near term cash, plus milestones and royalties
  • Promedior in its option agreement with Bristol-Myers Squibb with potential deal value of up to $1.25 billion
  • Unum Therapeutics in its strategic collaboration with Seattle Genetics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer, with potential deal value of $615 million
  • Foundation Medicine in its collaboration agreement and equity transaction with Roche, with total deal value in excess of $1 billion
  • F-star Alpha in its option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
  • Teva Pharmaceuticals in its acquisition of Labrys Biologics, for $200 million cash and up to $825 million
  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
  • bluebird bio in its global collaboration with Celgene and subsequent update for gene therapies to treat cancer with deal value up to $300 million
Public Offerings
  • aTyr Pharma in its $75 million initial public offering and $45 million equity financing, and earlier $76 million Series E financing
  • Ra Pharmaceuticals in its $105 million initial public offering
  • Dimension Therapeutics in its $72 million initial public offering
  • Blueprint Medicines in its $147 million initial public offering and $143 and $230 million follow-on offerings
  • Foundation Medicine in its $106 million initial public offering
  • Fate Therapeutics in its $40 million IPO, $30 million follow-on offering, and $57 million structured PIPE
  • Aerpio Therapeutics in its $40 million reverse merger and private placement
Venture Financings
  • Medicxi Ventures in its $22.5 million financing of Impact Biomedicines to develop treatments for myeloproliferative neoplasms and other cancers
  • SetPoint Medical in its $100 plus million in financings for its implantable neuromodulation devices
  • Arrakis Therapeutics in its $38 million financing to discover a new class of medicines directly targeting RNA
  • Cerevance in its $41 million aggregate funding and spin-out from Takeda Pharmaceutical for neuroscience
  • Corvidia Therapeutics in its $26 million financing and in-license of a clinical stage asset from AstraZeneca
  • Pronutria Biosciences in its $81.5 million financings for amino acid-based products
  • Scholar Rock in its $56 million financings for therapeutics that target specific growth factors
  • Unum Therapeutics in its $65 million financing for its anti-body directed cellular immunotherapies
  • Semma Therapeutics in its $44 million financing for stem cell therapies for Type 1 diabetes
  • Surface Oncology in its $35 million financing for cancer immunotherapies
  • Aerpio Therapeutics in its $60 million financings for vascular disease therapies

Recognition

Mr. Taft has been recognized by numerous legal guides for legal and life sciences industry expertise. In addition to the two listings noted above, Mr. Taft has also been named as a leading business lawyer by U.S. News-Best Lawyers (Biotechnology Law), LMG Life Sciences (Life Sciences Star), The Legal 500 United States (Healthcare: Life Sciences and Venture Capital and Emerging Companies), PLC Cross-border Life Sciences Handbook (Commercial and Partnering), IAM Patent 1000 (Licensing) and The International Who’s Who of Life Sciences Lawyers(Transactional).

Under his leadership, Goodwin’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for four out of the last five years (2013 through 2015, and 2017), LMG Life Sciences’ Venture Capital Law Firm of the Year (2016), and perennial nationwide recognition by Chambers USA.

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., 1997
Harvard Law School

(magna cum laude)

Ph.D., Chemistry, 1993
Massachusetts Institute of Technology
B.S., Chemistry, 1989
Yale University

(magna cum laude)

Clerkships

1997 to 1998 U.S. Court of Appeals for the Federal Circuit, Honorable Raymond C. Clevenger

Admissions

Bar

Massachusetts
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师